Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Study identifier:D4510C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients with Advanced Solid Malignancies including Malignant Lymphoma

Medical condition

Advanced solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1208

Sex

All

Actual enrollment

43

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 Jul 2012
Primary Completion Date: 01 Jul 2014
Study Completion Date: 01 Jul 2014

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria